EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Chromosome 14q loss is associated with adverse survival and a distinct transcriptional phenotype in IDH-wildtype glioblastoma

Nayuta Higa, Seiya Yokoyama, Toshiaki Akahane, Taiji Hamada, Hajime Yonezawa, Ryutaro Makino, Tomoko Takajo, Kei Matsuo, Mari Kirishima, Ikumi Kitazono, Yutaka Fujioka, Ryusuke Hatae, Daisuke Kuga, Shohei Nagasaka, Kohei Suzuki, Junkoh Yamamoto, Koji Yoshimoto, Akihide Tanimoto, Ryosuke Hanaya

Journal of Neuro-Oncology · 2026-11 · 180 (2)

DOI: 10.1007/s11060-026-05855-2 ↗
AbstractBibliografische Angaben

Abstract

Abstract Purpose In IDH-wildtype glioblastoma, prognostic biomarkers beyond MGMT promoter methylation remain limited. Chromosome 14q contains candidate tumor suppressors, yet the significance of arm-level 14q loss in molecularly defined glioblastoma is unclear. Methods Arm-level 14q status was inferred from coordinated 14q expression (Gaussian-mixture model) in bulk RNA sequencing of 215 Japanese IDH-wildtype glioblastomas and validated against methylation-array copy number ( n = 42). Associations with outcome and transcriptional programs were evaluated and assessed in CGGA ( n = 74) and TCGA ( n = 139) using the discovery-cohort threshold. Results RNA-seq-based calls agreed with array copy number in 40/42 cases (κ = 0.90). 14q loss (87/215, 40.5%) was associated with shorter overall ( p = 0.0053) and progression-free survival ( p = 0.0175), remaining prognostic in the prespecified multivariable model (hazard ratio 1.44, 95% confidence interval 1.02–2.01; p = 0.036). 14q loss and MGMT promoter hypomethylation were prognostically complementary (four-group p < 0.0001). Chromosome 14-excluded, purity-adjusted gene set enrichment analysis showed increased E2F-target and G2M-checkpoint and reduced oxidative-phosphorylation and lipid-metabolism programs in 14q-loss tumors. The survival association was reproduced in CGGA ( p = 0.0012) but not in TCGA ( p = 0.55), with significant heterogeneity (interaction p = 0.005). Conclusion RNA-seq-inferable 14q loss identifies a clinically adverse subgroup of Japanese IDH-wildtype glioblastoma, is complementary to MGMT promoter methylation, and is associated with a proliferation-high, oxidative-phosphorylation-low transcriptional state. The absence of this association in TCGA underscores the need for validation in additional population-diverse cohorts before clinical implementation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →